6-anilino-5,8-quinolinedione and Cardiac Hypertrophy studies

6-anilino-5,8-quinolinedione: structure given in first source; SRS-A & guanylate cyclase antagonist
6-anilino-5,8-quinolinedione : A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group.

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

Excerpt	Relevance	Reference
"We tested the hypothesis that a reduction in myocardial cyclic GMP would increase myocardial O2 consumption and that renal hypertension (One Kidney-One Clip, 1K1C)-induced cardiac hypertrophy would change this relationship."	7.69	Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy. ( Sadoff, JD; Scholz, PM; Tse, J; Weiss, HR, 1997)
"We tested the hypothesis that a reduction in myocardial cyclic GMP would increase myocardial O2 consumption and that renal hypertension (One Kidney-One Clip, 1K1C)-induced cardiac hypertrophy would change this relationship."	3.69	Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy. ( Sadoff, JD; Scholz, PM; Tse, J; Weiss, HR, 1997)

Research

Studies (1)

Authors

Other Studies

1 other study available for 6-anilino-5,8-quinolinedione and Cardiac Hypertrophy

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80